MedPath

Clinical Evaluation of Etafilcon A Contact Lenses Using a Novel Manufacturing Technology

Not Applicable
Completed
Conditions
Visual Acuity
Interventions
Device: 1-DAY ACUVUE® MOIST
Registration Number
NCT03962790
Lead Sponsor
Johnson & Johnson Vision Care, Inc.
Brief Summary

This study is a multi-site, randomized, double-masked, 2×2 crossover design, 1-week dispensing study. Subjects will wear both Test and Control lenses in each eye in a random order for 1-week each as a daily disposable modality with a wash-out period of 1 week between the wearing periods.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
95
Inclusion Criteria
  • Potential subjects must satisfy all of the following criteria to be enrolled in the study:

    1. The subject must read, understand, and sign the STATEMENT OF INFORMED CONSENT and receive a fully executed copy of the form.
    2. Appear able and willing to adhere to the instructions set forth in this clinical protocol.
    3. Must be at least 18 and not more than 70 years of age (including 70) at the time of screening.
    4. The subject must be a habitual and adapted wearer of hydrogel daily disposable brand contact lenses in both eyes (at least 1 month of daily wear).
    5. The subject must have normal eyes (i.e., no ocular medications or infections of any type).
    6. The subject's required spherical contact lens prescription must be in the range of -0.50 to -6.00 D in each eye.
    7. The subject's refractive cylinder must be < 0.75D in each eye.
    8. The subject must have best corrected visual acuity of 20/25 or better in each eye.
Exclusion Criteria
  • Potential subjects who meet any of the following criteria will be excluded from participating in the study:

    1. Currently pregnant or lactating (subjects who become pregnant during the study will be discontinued).
    2. Any systemic disease, autoimmune disease, or use of medication that may interfere with contact lens wear.
    3. Any previous, or planned, ocular or interocular surgery (e.g., radial keratotomy, PRK, LASIK, etc.).
    4. Any ocular infection.
    5. Any corneal distortion resulting from previous hard or rigid gas permeable contact lens wear.
    6. Monovision or multi-focal contact lens correction.
    7. Participation in any contact lens or lens care product clinical trial within 14 days prior to study enrollment.
    8. History of binocular vision abnormality or strabismus.
    9. Any infectious disease (e.g., hepatitis, tuberculosis) or a contagious immunosuppressive disease (e.g., HIV, by self-report).
    10. Suspicion of or recent history of alcohol or substance abuse.
    11. History of serious mental illness.
    12. History of seizures.
    13. Employee or immediate family member of an employee of clinical site (e.g., Investigator, Coordinator, Technician)
    14. Any ocular allergies, infections or other ocular abnormalities that are known to interfere with contact lens wear and/or participation in the study. This may include, but not be limited to entropion, ectropion, extrusions, chalazia, recurrent styes, glaucoma, history of recurrent corneal erosions, aphakia, or corneal distortion
    15. Any Grade 3 or greater slit lamp findings (e.g., edema, corneal neovascularization, corneal staining, tarsal abnormalities, conjunctival injection) on the Food and Drug Administration (FDA) classification scale
    16. Any previous history or signs of a contact lens-related corneal inflammatory event (e.g., past peripheral ulcer or round peripheral scar), or any other ocular abnormality that may contraindicate contact lens wear.

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
Test/Control1-DAY ACUVUE® MOISTEligible subjects that are habitual wearers of hydrogel daily disposable contact lenses in both eyes will be randomly assigned to one of two sequences, (Test/Control) or (Control/Test).
Control/Test1-DAY ACUVUE® MOISTEligible subjects that are habitual wearers of hydrogel daily disposable contact lenses in both eyes will be randomly assigned to one of two sequences, (Test/Control) or (Control/Test).
Primary Outcome Measures
NameTimeMethod
Overall Comfort Score1-Week Follow-up

Overall comfort score was assessed using the Contact Lens User Experience (CLUE) questionnaire. CLUE is a validated patient-reported outcomes (PRO) questionnaire to assess patient-experience attributes of soft contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Derived CLUE scores using Item Response Theory (IRT) follow a normal distribution with a population average score of 60 (standard deviation \[SD\] 20), where higher scores indicate a more favorable/positive response. A 5-point increase in an average CLUE score translates into 10% shift in the distribution of scores for the population of soft disposable contact lens wearers.

Overall Vision Score1-Week Follow-up

Overall quality of vision was assessed using the Contact Lens User Experience (CLUE) questionnaire. CLUE is a validated patient reported outcomes (PRO) questionnaire to assess patient-experience attributes of soft contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Derived CLUE scores using Item Response Theory (IRT) follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response. A 5-point increase in an average CLUE score translates into 10% shift in the distribution of scores for the population of soft disposable contact lens wearers.

Secondary Outcome Measures
NameTimeMethod
LogMAR Visual Performance Scale1-Week follow-up

Visual acuity measured via Early Treatment Diabetic Retinopathy Study (ETDRS) charts (logMAR) can take on any possible value. A value of 0.0 logMAR equates to 20/20 vision on a Snellen Scale. Lower values indicate better visual performance. The average visual performance is reported for each lens type on high contrast dim light and low contrast bright light.

Average Daily Wear Time1-Week follow-up

Average daily wear time was calculated as the number of hours between participants reported time of insertion and time of removal of the study lenses, on an average day, at 1-Week follow-up evaluation.

Trial Locations

Locations (6)

Eyecare Professionals of Powell

🇺🇸

Powell, Ohio, United States

Manhattan Vision Associates

🇺🇸

New York, New York, United States

Eyecare Associates, LLP

🇺🇸

Bloomington, Illinois, United States

Frazier Vision

🇺🇸

Tyler, Texas, United States

Maitland Vision Center

🇺🇸

Maitland, Florida, United States

Sacco Eye Group

🇺🇸

Vestal, New York, United States

© Copyright 2025. All Rights Reserved by MedPath